January 21, 2026 – The Japan Pharmaceutical Manufacturers Association (JPMA) has joined forces with INCATE (INCubator for Antimicrobial Therapies in Europe), strengthening global collaboration to support innovation and solutions against antimicrobial resistance (AMR).

INCATE brings together academic research, industry, investors, and public sector organizations to support early-stage innovators developing new antimicrobial therapies, diagnostics, and tools to combat AMR. By joining, JPMA underscores its commitment to helping innovators and advancing solutions to this global health emergency.

“Antimicrobial resistance is a global threat that requires collective action,” said (Hideki Maki, Ph.D., Principal Scientist, Shionogi & Co., Ltd., JPMA). “By partnering with INCATE, we hope to encourage innovation and ensure that promising ideas can translate into impactful solutions for patients worldwide.”

JPMA’s engagement will help broaden INCATE’s international reach, creating new opportunities for collaboration between European and Japanese stakeholders. This partnership is expected to accelerate the development of innovative therapies and reinforce the importance of cross-border cooperation in addressing AMR.

“We are honored to join forces with JPMA,” said Derry Mercer, member of the INCATE Management Team. “Their expertise and global perspective will be invaluable as we work together to support innovators and strengthen the pipeline of new solutions against AMR.”

The collaboration is already underway with the co-hosted webinar, “Promoting Antibacterial Drug Development through Public–Private Partnership.” The event aimed to stimulate innovation in antimicrobial drug discovery and expand the global community of experts in the antibacterial field. It provided a platform to build an international network linking academia, startups, industry, and regulators, fostering early-stage collaboration — particularly in emerging areas such as phage therapy.

This partnership underscores a shared commitment to innovation, sustainability, and global health security, reinforcing and expanding Japan–Europe cooperation in the face of rising antimicrobial resistance.

About JPMA
The Japan Pharmaceutical Manufacturers Association (JPMA) is a voluntary association comprising research-oriented pharmaceutical companies. JPMA is dedicated to promoting research and development of innovative medicines, contributing to patient health, and advancing global health solutions. Please visit JPMA

About INCATE
INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs, and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research AntiResist, the University of Basel are the academic founding members of INCATE with the University of Basel acting as the host. Together with the four industry partners Basilea, Roche, Shionogi and MSD as well as other organizations, funders and investors, INCATE want to ensure that the pipeline of new antibiotics and technology platforms is filled and strengthened.

For more information please contact:
helena.costa.pereira@incate.net or +49 176 46172549
www.incate.net
LinkedIn | BlueSky @INCATE